Cyclophosphamide News and Research

RSS
Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.
Novel treatment strategy during transplantation surgery could spare patients from rejection

Novel treatment strategy during transplantation surgery could spare patients from rejection

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Matching the right tumor with the right drug

Matching the right tumor with the right drug

New study reveals way to combat drug-resistant tumors

New study reveals way to combat drug-resistant tumors

Immunotherapy maintenance shows promise in NSCLC

Immunotherapy maintenance shows promise in NSCLC

NICE approves MabThera for treating severe forms of GPA and MPA

NICE approves MabThera for treating severe forms of GPA and MPA

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

Adding drug to presurgery chemotherapy improves results for women with triple-negative breast cancer

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

New drug combination therapy effective for patients with HER2-positive breast cancer

New drug combination therapy effective for patients with HER2-positive breast cancer

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Study reveals that Medicaid beneficiaries with lupus not following treatment plans

Study reveals that Medicaid beneficiaries with lupus not following treatment plans

immatics biotechnologies closes €34 million Series D financing round

immatics biotechnologies closes €34 million Series D financing round

Powerful new option for treating vasculitis

Powerful new option for treating vasculitis

Research opens potential new avenue for cancer treatment

Research opens potential new avenue for cancer treatment

NIH-funded study finds that rituximab is as effective as standard therapy for severe vasculitis

NIH-funded study finds that rituximab is as effective as standard therapy for severe vasculitis

Genentech announces that Phase III CLL11 study meets primary endpoint

Genentech announces that Phase III CLL11 study meets primary endpoint

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Primary mediastinal B-cell lymphoma has better outcome with more dose-intense regimens

Primary mediastinal B-cell lymphoma has better outcome with more dose-intense regimens

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM

DelMar Pharmaceuticals reports positive results from VAL-083 Phase I/II clinical trial in patients with GBM